PillRx only · Injection, Solution · Subcutaneous
Ustekinumab-Stba
Brands: Steqeyma · Ustekinumab
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US3 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$3962.440
Latest avg · Jul 22, 2026
-1%
Since Jun 17, 2026
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.6K
Rx · 2026 Q1
1.5K
Units dispensed
4
Quarters · since 2025 Q2
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| CELLTRION USA, Inc. | unknown | 3 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.